RefleXion Medical Files FDA Clearance Request for New Tumor Tracking Radiotherapy Technology

RefleXion Medical has filed for FDA clearance of Anchor Point Tracking, a tumor-targeting technology for its new X2 radiotherapy platform.

A California medical device company has asked federal regulators to clear a new autonomous tumor-tracking system intended to advance radiation cancer treatment. RefleXion Medical, based in Hayward, California, submitted a 510(k) premarket notification to the U.S. Food and Drug Administration seeking clearance for its Anchor Point Tracking technology. The system is designed to work with the company's new RefleXion X2 platform and falls under its existing SCINTIX autonomous radiotherapy brand. CEO and President Todd Powell described Anchor Point Tracking as "the next major advancement in autonomous radiotherapy," though the full statement was not available beyond that excerpt in the reporting. The 510(k) pathway is a standard FDA route for medical devices that are substantially equivalent to already-cleared devices. RefleXion Medical describes itself as an external beam theranostic oncology company — a field combining cancer therapy and diagnostics. The submission marks a regulatory milestone for the company's next-generation platform, though FDA clearance has not yet been granted.

Why it matters

FDA clearance, if granted, could bring a new level of autonomous tumor tracking into clinical radiation therapy, potentially improving precision in cancer treatment. The outcome of this submission will determine whether the X2 platform's tracking capability can be marketed and used in U.S. medical facilities.

What's next

The FDA will review the 510(k) submission and issue a clearance decision, though no timeline was specified in the available reporting.

Key facts

• RefleXion Medical is headquartered in Hayward, California
• The company submitted a 510(k) premarket notification to the FDA for Anchor Point Tracking
• Anchor Point Tracking is designed for use with the new RefleXion X2 platform
• The technology is part of the company's SCINTIX autonomous radiotherapy line
• CEO Todd Powell called it 'the next major advancement in autonomous radiotherapy'
• RefleXion describes itself as an external beam theranostic oncology company

Bias & framing notes

Two of the three sources (Times Argus and Rutland Herald) were behind paywalls and provided no usable reporting. The sole substantive source is a Business Wire press release, which is a company-issued document and inherently promotional in framing. No independent journalistic sources were available to corroborate or contextualize the claims.

NewsClear — neutral news & congressional tracking · Bill of the Week